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The elimination of tuberculosis (TB) is threatened 
by an apparent increase in the level of resistance in 
Mycobacterium tuberculosis. In the Netherlands, 
where the majority of TB patients are migrants, resist-
ance may also be increasing. We conducted a retro-
spective study, using 18,294 M. tuberculosis isolates 
from TB cases notified between 1993 and 2011. We 
investigated the trends in antituberculosis drug resist-
ance, focusing on the country of birth of the patients 
and whether resistance had developed during treat-
ment or was the result of transmission of resistant 
M. tuberculosis strains. For both scenarios, we deter-
mined whether this had happened in or outside the 
Netherlands. Antituberculosis drug resistance was 
found in 13% of all cases analysed and showed an 
increasing trend among patients who had been born 
in the Netherlands (p<0.001) and a decreasing trend 
among foreign-born (p=0.02) over the study period. 
Since 2005, the proportion of M. tuberculosis resistant 
strains among all strains tested has increased in both 
groups (p=0.03 and p=0.01, respectively). Overall, we 
found a significantly increasing trend when excluding 
streptomycin resistance (p<0.001). The trend was most 
markedly increased for isoniazid resistance (p=0.01). 
Although resistance was mainly due to transmission 
of resistant strains, mostly outside the Netherlands 
or before 1993 (when DNA fingerprinting was not sys-
tematically performed), in some cases (n=45), resist-
ance was acquired in the Netherlands. We conclude 
that antituberculosis drug resistance is increasing 
in the Netherlands, mostly related to migration from 
high TB-incidence countries, but also to domestic 
acquisition.
Introduction 
Resistance to antituberculosis drugs is emerging in 
several areas worldwide. In eastern Europe and cen-
tral Asia, hotspots of multidrug-resistant tuberculosis 
(MDR-TB) are present, with nearly a third of the new 
and three quarters of previously treated TB cases diag-
nosed as having MDR-TB in some countries [1]. This is 
of great concern, considering the limited drug options 
to safely and effectively treat these resistant forms of 
TB. Distinguishing between transmission of a resistant 
M. tuberculosis strain and development of resistance 
during treatment has important consequences for TB 
control programmes [2].
The elimination of TB (defined as less than one case 
per million population) – a World Health Organization 
(WHO) target for 2050 [3] – is threatened by an appar-
ent increase in multidrug resistance worldwide [1,4,5]. 
Global trends, however, are hard to interpret as a result 
of incomplete coverage of surveillance data. In many 
regions in Sub-Saharan Africa, and also in central and 
eastern Europe and India, drug resistance surveillance 
data are lacking, mainly as a result of inadequate labo-
ratory infrastructure [1].
In the Netherlands, a low TB-incidence country with 
approximately 1,000 new registered TB cases annually 
and an incidence of 6.0 per 100,000 population in 2011 
[6], nationwide surveillance of TB has been in place 
since 1993. Until recently, all local mycobacteriology 
laboratories routinely sent their M. tuberculosis com-
plex isolates to the WHO-accredited National Reference 
Laboratory at the National Institute for Public Health 
and the Environment (RIVM) for identification, drug 
susceptibility testing (DST) and molecular typing. 
After 2011, some local laboratories started to screen 
for resistance against first-line drugs themselves, but 
when resistance is diagnosed, the results are con-
firmed at the National Reference Laboratory, where DST 
is broadened to other drugs. A DNA fingerprint of each 
M. tuberculosis isolate is produced, to guide investiga-
tion of epidemiological links between TB cases.
In the mid-1990s, a descriptive study showed that 
the majority of TB cases with resistant strains in the 
Netherlands were migrants [7]. Recent increases in 
the proportion of migrants among TB patients in the 
Netherlands [6], in the prevalence of drug resistance 
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in many of the migrants’ country of origin [8] as well 
as changes in the composition of the migrant popula-
tion might have influenced the resistance situation in 
the Netherlands over the last couple of years [6,9]. To 
improve our understanding of the extent and origin of 
M. tuberculosis resistance in the Netherlands, we con-
ducted a retrospective study of all TB cases notified 
between 1993 and 2011. We investigated the trends in 
resistance to antituberculosis drugs in this period, in 
relation to the country of origin of the patients. In addi-
tion, we assessed the extent to which drug resistance 
was due to transmission of resistant strains or was 
possibly acquired during previous treatment. For both 
scenarios, we determined whether this had occurred in 
or outside the Netherlands.
Methods
Data sources and study population
Data were obtained from three sources and matched 
on the basis of postal code, date of birth and sex. The 
resulting data set consisted of anonymous data. We 
used data from three sources: firstly, the Netherlands 
Tuberculosis Register after approval by the registry 
committee. These data, systematically collected at 
Municipal Health Services, include information on 
patient characteristics, treatment history, case find-
ing and treatment outcome. Secondly, data from the 
National Reference Laboratory were used, which con-
tain information on drug susceptibility and DNA pro-
files of the bacterial isolates. Between 1993 and 2009, 
nationwide fingerprinting of M. tuberculosis isolates 
using IS6110 restriction fragment length polymorphism 
(RFLP) typing was performed at the National Reference 
Laboratory; after 2009, RFLP typing was replaced by 
variable number tandem repeat (VNTR) typing [10,11]. 
Thirdly, we received the results of epidemiological 
investigation of clustered cases, which is routinely car-
ried out by TB public health nurses in the Netherlands.
All notified M. tuberculosis culture-positive cases 
between 1993 and 2011 were included in the study. 
Isolates with missing DST results, including those 
tested in local laboratories, which participate in qual-
ity control programmes, were considered suscepti-
ble. If patients had multiple isolates, only isolates of 
M. tuberculosis strains with different DNA fingerprints 
were included in the database: subsequent isolates 
representing the same M. tuberculosis strain were 
excluded.
Drug resistance: trends and origin 
Standard DST for the following first-line drugs was per-
formed for each isolate: isoniazid, rifampicin, strepto-
mycin, ethambutol and pyrazinamide. Susceptibility to 
the following second-line drugs was only assessed if 
the isolate was resistant to isoniazid and/or rifampicin: 
amikacin, capreomycin, ciprofloxacin, clarithromycin, 
clofazimine, cycloserine, kanamycin, linezolid, moxi-
floxacin, ofloxacin, protionamide and rifabutin. Until 
2004, the absolute concentration method was the 
standard DST method used [12], but this was replaced 
thereafter by the mycobacteria growth indicator tube 
(MGIT) assay [13]. Patients were classified according 
to the DST result as having drug-susceptible isolates 
if the causative bacteria were sensitive to the first-line 
drugs tested or as having drug-resistant isolates if 
resistance to at least one drug was detected.
Trends in resistance were analysed for the study period. 
Extensively drug-resistant TB was only detected rarely 
and involved in total three cases in 2009 to 2011 [6]. 
Drug resistance rates (percentage of resistant isolates 
among all isolates tested for drug susceptibility) were 
described for those born in the Netherlands and those 
who were born abroad. 
A distinction was made between primary drug resist-
ance (PDR), i.e. drug resistance in new TB cases and 
acquired drug resistance (ADR), i.e. drug resistance 
in previously treated TB cases. For foreign-born ADR 
patients, we compared the year of entry into the 
Netherlands with the year of previous TB treatment 
to assess whether resistance had been acquired in 
the Netherlands or abroad. ADR patients born in the 
Netherlands were considered to have acquired resist-
ance in the Netherlands.
Transmission of drug-resistant TB
For PDR cases, we assessed where transmission of the 
resistant strain most probably occurred, based on the 
DNA fingerprinting of M. tuberculosis isolates and the 
subsequent results of cluster investigation. 
Clusters were defined as groups of patients having iso-
lates with identical RFLP or VNTR patterns or, if strains 
had fewer than five IS6110 copies, identical polymor-
phic GC-rich sequence RFLP patterns [14]. During 2004 
to 2008, within the framework of a nationwide evalu-
ation following the introduction of VNTR typing, both 
RFLP and VNTR typing were performed for all isolates 
and strains could thus belong to both an RFLP and a 
VNTR cluster [15]. The agreement in clustering between 
both methods was about 80%. In order to prevent 
strains being part of two different clusters, we used 
the RFLP patterns to cluster isolates from before 2009 
and VNTR patterns to cluster strains isolated in 2009 
or thereafter. Cases were divided into those whose 
M. tuberculosis strain had a unique DNA fingerprint 
and those with a clustering fingerprint. The first case 
in each cluster, based on the diagnosis date, was 
classified as unique. After matching the Netherlands 
Tuberculosis Register data with data from the National 
Reference Laboratory, a number of clusters were broken 
up as a result of a 15% mismatch, which occurred due 
to incorrect or incomplete data on identifying variables 
(e.g. country of birth, sex, postal code) that link the 
cases. Cases for whom the data could not be matched 
were excluded from the analysis. This resulted in the 
formation of ‘clusters’ with only one case left, which 
were excluded from further analysis.
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PDR cases were classified into three groups accord-
ing to a classification model previously described [16]: 
(i) PDR cases with an M. tuberculosis strain that had 
a unique DNA fingerprint, as well as clustered cases 
without a potential source case (i.e. without a pre-
ceding pulmonary TB case in the cluster) were con-
sidered infected abroad or before 1993; (ii) clustered 
PDR cases with a potential source case, but without a 
confirmed or likely epidemiological link to a previous 
case in the cluster were considered possibly infected 
in the Netherlands; and (iii) clustered PDR cases with a 
potential source case and a confirmed or likely epide-
miological link with a previous case in the cluster were 
considered definitely infected in the Netherlands. An 
epidemiological link was considered ‘confirmed’ when 
a social contact with another patient in the cluster had 
been documented in an interview with the respective 
patients or ‘likely’ if the patients visited the same place 
at the same time (without being aware of each other’s 
presence) [17].
Statistical analysis
We used logistic regression analyses to assess the sta-
tistical significance of trends in resistance, with antitu-
berculosis drug resistance as dichotomous outcome 
variable and year of diagnosis as continuous independ-
ent variable. A trend was considered significant if the 
regression coefficient for year of diagnosis differed 
significantly from 0. A positive coefficient indicated an 
increasing trend and a negative coefficient indicated a 
decreasing trend. We calculated 95% confidence inter-
vals (CIs) for drug resistance percentages over time, 
assuming the number of resistant samples was nor-
mally distributed. 
Univariate and multivariate logistic regression analy-
ses were used to examine which determinants were 
associated with resistance (dependent variables). 
Determinants evaluated were demographic variables 
– i.e. sex, age, living in an urban area (in one of the 
four largest cities in the Netherlands (Amsterdam, 
Rotterdam, The Hague, Utrecht), being foreign-born, 
length of time of residence in the Netherlands and 
belonging to a risk group (i.e. a group with a high risk 
of exposure to TB, such as drug users, asylum seekers, 
illegal residents), Bacillus Calmette–Guérin (BCG) vac-
cination, previous treatment history and having pulmo-
nary TB. 
Table 1
Determinants of resistance to at least one antituberculosis drug in patients with culture-positive tuberculosis in the 
Netherlands, 1993–2011
Characteristic
Isolates with 
DST results 
n=14,820
All isolates
n=14,959
Resistant 
isolates
n=1,890
Susceptible 
isolates 
n=12,930
Crude OR
(95% CI)
Adjusted ORb
(95% CI)
n (%)a n (%)a n (%)a n (%)a
Male sex 8,857 (60) 8,941 (60) 1,106 (58) 7,751 (60) 0.94 (0.86–1.04) 1.02 (0.88–1.18)
Mean age in years (SD) 41 (20) 41 (20) 33 (15) 42 (20) 0.98 (0.97–0.98)c 0.98 (0.97–0.98)c
Living in an urban area 5,150 (35) 5,218 (35) 653 (35) 4,497 (35) 0.99 (0.89–1.10) 1.09 (0.94–1.28)
Foreign-born 10,165 (69) 10,257 (69) 1,590 (84) 8,575 (66) 2.69 (2.37–3.06)c 1.92 (1.55–2.38)c 
Median number of years in the 
Netherlands before diagnosis (IQR)d 5 (1–14) 5 (1–14) 3 (1–9) 5 (1–15) 0.97 (0.97–0.98)
c 0.99 (0.97–1.00)
BCG vaccinatione 4,124 (50) 4,182 (50) 667 (67) 3,457 (48) 2.20 (1.92–2.53)c 1.06 (0.87–1.28)
Belonging to a risk group 9,265 (63) 9,335 (62) 1,390 (74) 7,875 (61) 1.78 (1.60–1.99)c 1.15 (0.96–1.37)
Previous TB treatmente 533 (4) 539 (4) 122 (8) 411 (4) 2.19 (1.78–2.70)c 2.31 (1.71–3.13)c 
Median number of years between 
diagnosis and previous treatment (IQR)f 21 (4–50) 21 (5–50) 5 (2–16) 26 (6–52) 0.96 (0.95–0.97)
c 0.98 (0.96–1.00)
Having pulmonary TB or pulmonary and 
extrapulmonary TB 10,015 (68) 10,112 (68) 1,243 (66) 8,772 (68) 0.91 (0.82–1.01) 0.92 (0.79–1.07)
BCG: Bacillus Calmette–Guérin; CI: confidence interval; DST: drug susceptibility testing; IQR: interquartile range; OR, odds ratio; SD: standard 
deviation; TB: tuberculosis.
a  Data are presented as number (percentage), unless indicated otherwise.
b  OR adjusted for sex, age, living in an urban area (Amsterdam, Rotterdam, The Hague, Utrecht), being born in the Netherlands/foreign born, 
being vaccinated with BCG, belonging to a risk group (i.e. a group with high risk of exposure to TB, such as drug users, asylum seekers, 
illegal residents), had previous treatment and had pulmonary TB.
c  P<0.05.
d  Calculated for foreign-born patients.
e  Data were missing for BCG vaccination (888 resistant isolates; 5,648 susceptible isolates) and previous TB treatment (268 resistant 
isolates; 1,464 susceptible isolates).
f  Calculated for previously treated patients.
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Multivariate logistic regression was used to adjust 
for possible confounders. Variables with p<0.05 in 
the univariate analysis, as well as variables that 
were expected to be related to the outcome measure 
were used. In addition, differences between ADR and 
PDR cases were analysed using multivariate logistic 
regression with type of drug resistance (ADR/PDR) as 
dichotomous dependent variable and drug-specific 
resistance, age and being foreign-born as covariates. 
Crude and adjusted odds ratios (ORs) are presented 
with 95% CIs. All statistical analyses were performed 
using SPSS version 19. A significance level of 0.05 was 
used throughout.
Results
During 1993 to 2011, 18,294 isolates were collected 
from 18,274 notified TB cases. A total of 15,601 iso-
lates (85%) could be matched with the Netherlands 
Tuberculosis Register data, of which 14,959 (96%) were 
M. tuberculosis cultures. A total of 14,820 of these iso-
lates (99%) had DST results and 1,890 (13%) of these 
strains showed resistance to at least one antituber-
culosis drug. Resistance was found in 1,500 (12%) of 
12,678 new cases and 122 (23%) of all 539 previously 
treated patients. Resistance to isoniazid and strepto-
mycin was most common, while rifampicin, ethambu-
tol and pyrazinamide resistance and MDR-TB (defined 
as resistance to at least isoniazid and rifampicin) were 
less frequently observed (data not shown). The mean 
age of M. tuberculosis-positive TB cases was 41 years 
(SD: 20). Of the 14,959 M. tuberculosis isolates, 8,941 
(60%) were from cases who were male; 5,218 (35%) 
lived in an urban area; 10,257 (69%) were foreign-born 
and 10,112 (68%) had pulmonary TB (including those 
with pulmonary TB and extrapulmonary TB). Of 8,376 
patients with data on vaccination and resistance sta-
tus, 4,182 (50%) were BCG vaccinated (Table 1).
Trends in drug resistance
The resistance rate was considerably higher in for-
eign-born TB patients than in patients born in the 
Netherlands (16% vs 6%, p<0.001). Among those who 
were foreign-born, trend analysis showed a slightly 
decreasing trend in the proportion of resistant isolates 
during 1993 to 2005 (p value for trend (ptrend)= 0.01), 
followed by a significantly increasing trend until 2011 
(ptrend = 0.01, Figure 1). However, the 95% CIs for 2005 
and 2011 overlap slightly (10.3–14.3 and 13.7–19.1, 
respectively). Among patients born in the Netherlands, 
resistance increased from 5% (95% CI: 3.0–6.8) in 
1993 to 10% (95% CI: 6.8–13.9) in 2011 (ptrend <0.001) 
(Figure 1). For the total population, the proportion of 
isolates resistant to any TB drug fluctuated around 12% 
until 2005, but then increased significantly from 10.7% 
(95% CI: 9.1–12.3) in 2005 to 15% (95% CI: 12.6–17.0) in 
2011 (ptrend <0.001) (data not shown).
We found a significantly increasing trend for drug 
resistance, when excluding streptomycin resistance, 
from 7.1% (95% CI: 5.7–8.5) in 1993 to 11.1% (95% CI: 
9.2–13.0) in 2011 (Figure 2, ptrend <0.001). Streptomycin 
has not been used in the Netherlands since 1996, when 
new TB treatment guidelines were issued, and resist-
ance to it decreased from 5.8% (95% CI: 4.5–7.1) in 
1993 to 3.7% in 2011 (95% CI: 2.5–4.9) (ptrend <0.001). 
In particular, the percentage of isolates with isonia-
zid resistance increased significantly from 2.9% (95% 
CI: 2.0–3.8) in 1993 to 5.7% in 2011 (95% CI: 4.3–7.1) 
(Figure 2, ptrend = 0.01). The same applied to MDR-TB: 
from 1.1% (95% CI: 0.5–1.7) in 1993 to 2.5% (95% CI: 
1.5–3.5) in 2011 (Figure 2, ptrend <0.001). 
When analysing cases by country of birth, and exclud-
ing streptomycin resistance, resistance increased 
from 2.3% (95% CI: 1.0–3.6) in 1993 to 8.1% (95% CI: 
4.8–15.4) in 2011 among cases born in the Netherlands 
and increased from 10.6% (95% CI: 8.3–12.9) in 1993 to 
12.2% (95% CI: 9.8–21.8) in 2011 among foreign-born 
cases. Isoniazid resistance increased from 0.4% (95% 
CI: 0.0–0.9) in 1993 to 4.4% (95% CI: 1.9–11.1) in 2011 
among cases born in the Netherlands and increased 
Figure 1
Trend in the proportion of Mycobacterium tuberculosis 
isolates with resistance to at least one antituberculosis 
drug in the Netherlands, for patients born in the 
Netherlands and foreign-born patients, 1993–2011
CI: confidence interval.
Data from the National Reference Laboratory at the National 
Institute for Public Health and the Environment (RIVM). The 
number of isolates tested for drug susceptibility was lower 
in 2011 because local laboratories started to test for drug 
susceptibility as well.  Not all isolates were sent to the National 
Reference Laboratory any more.
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from 4.7% (95% CI: 3.1–6.3) in 1993 to 6.1% (95% CI: 
4.4–16.0) in 2011 among those who were foreign-born.
Origin of drug resistance
Multivariate analyses showed that younger age, being 
foreign-born and previous TB treatment were inde-
pendently related to resistance, while sex, living in an 
urban area, BCG vaccination, belonging to a risk group 
and having pulmonary TB were unrelated (Table 1). The 
significant univariate association between BCG vacci-
nation and resistance may be explained by the fact that 
patients who were foreign-born were more likely to be 
vaccinated than those born in the Netherlands. Drug-
resistant isolates from foreign-born cases more often 
expressed rifampicin resistance and MDR than drug-
resistant isolates from cases born in the Netherlands 
(Table 2).
For 1,622 (86%) of all 1,890 patients with drug-resist-
ant isolates, information on previous TB treatment was 
available. Of these, 122 (8%) had been treated previ-
ously and 1,500 (92%) had not been treated before. 
Consequently, 8% of all resistant cases for whom infor-
mation on previous treatment was available were classi-
fied as ADR and 92% as PDR. This corresponds to 0.8% 
and 10% of all 14,959 TB cases analysed, respectively. 
In a multivariate analysis, we found that rifampicin 
resistance and MDR-TB were more associated with ADR 
than PDR. We also found that ADR patients were older 
than PDR patients (Table 3).
The percentage of ADR cases was not different 
between patients born in the Netherlands and those 
who were foreign-born (Table 2). Time since previous 
treatment was much longer in ADR cases born in the 
Netherlands (mean: 22 years; SD: 19) than in foreign-
born patients (mean 7 years; SD: 9); p<0.001). Two of 
16 ADR patients born in the Netherlands were sec-
ond-generation migrants as at least one parent had 
been born abroad. For nine ADR patients born in the 
Netherlands, the parents’ country of birth was not reg-
istered. Of 92 foreign-born ADR patients with known 
date of entry into the Netherlands, 49 had previously 
been treated before entry and were thus considered to 
have acquired resistance abroad. A total of 29 foreign-
born ADR patients had previously been treated after 
entry into the Netherlands and most probably acquired 
resistance or additional resistance in the Netherlands. 
For 14 foreign-born ADR patients, it was unknown 
where they acquired resistance, as the year of previous 
treatment coincided with the year of entry.
Transmission of drug-resistant TB
Of all 14,959 isolates, 14,913 (99.7%) DNA finger-
prints were generated. Due to the 15% mismatch with 
Netherlands Tuberculosis Register data, 454 clusters 
Figure 2
Trends in the proportion of Mycobacterium tuberculosis isolates resistant to first-line antituberculosis drugs, the 
Netherlands, 1993–2011
MDR: multidrug resistance, defined as resistance to at least isoniazid and rifampicin.
Percentages calculated as the number of resistant isolates divided by the total number of isolates tested for drug susceptibility. Resistance 
to isoniazid and streptomycin is not shown (only mono-resistance and MDR).
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consisted of only one case and were excluded from fur-
ther analysis. Of the resulting 14,459 isolates, 8,330 
(58%) were unique, of which 1,675 (20%) were the first 
case in a cluster; and 6,129/14,459 (42%) were clus-
tered cases. 
The total number of clusters was 1,676 and the median 
cluster size was 6 (interquartile range: 3–19). Of the 
1,676 clusters, 420 (25%) contained at least one case 
with resistant TB. Epidemiological cluster investigation 
was performed for 5,594 (91%) of all 6,129 clustered 
cases: an epidemiological link was confirmed in 1,674 
(30%) clustered cases, likely in 923 (17%) clustered 
cases and could not be determined in 2,997 (54%) clus-
tered cases.
PDR cases (n=1,445) were classified according to 
a transmission classification model (Figure 3): 129 
cases (9%) were definitely infected in the Netherlands, 
404 cases (28%) possibly and 912 cases (63%) were 
infected abroad or before 1993, when DNA fingerprint-
ing was not systematically performed. PDR patients 
born in the Netherlands more often had clustered iso-
lates than foreign-born PDR patients (132 (54%) vs 469 
(39%), p<0.001) and were more likely to have a con-
firmed epidemiological link with a previous case in the 
cluster (54 (22%) vs 75 (6%), p<0.001) (data not shown).
Discussion
This study, based on a large number of cases and 
molecular typing data from the Netherlands, covering 
many years, revealed that antituberculosis drug resist-
ance has increased since 1993 in patients born in the 
Netherlands and since 2005 in those foreign-born, and 
that resistance was more frequent among foreign-born 
patients. The increasing trend was mainly related to 
an increase in resistance to isoniazid, the cornerstone 
of first-line treatment. Furthermore, more than 90% of 
the drug resistance seen was a result of transmission. 
Our classification model suggests that transmission 
of resistant strains occurred in more than 60% of the 
cases before 1993 or abroad, and in 9% of the cases 
definitely in the Netherlands. Although ADR was rare, 
and mainly related to previous treatment abroad, in 
45/122 cases it was associated with previous treat-
ment failure in the Netherlands. Patient files should be 
retrieved and treatment history examined to gain more 
insight into the possible acquisition of resistance in 
the Netherlands.
The impact of the unexpected increase in antituber-
culosis drug resistance among patients born in the 
Netherlands is likely to be limited, because the major-
ity of TB drug resistance is still mainly found in foreign-
born patients, as reported previously [7].
The largest increase has been seen since 2005–06, 
when resistance among foreign-born patients has also 
been increasing. We suspect that the increase might 
be a result of enhanced migration from TB-endemic 
countries with high rates of TB drug resistance [18]. 
Concomitant intermingling of people born in the 
Netherlands and people with different ethnic back-
grounds born outside the Netherlands might have 
resulted in the spread of drug-resistant TB. This might 
explain the increase in isoniazid resistance, as such 
Table 2
Comparison of Mycobacterium tuberculosis isolates with resistance to at least one antituberculosis drug from tuberculosis 
patients born in and outside the Netherlands, 1993– 2011
Characteristic
Foreign-born 
n=1,590
Born in the 
Netherlands
n=300
Crude odds ratio 
(95% CI)
n (%)a n (%)a
Drug resistance
Isoniazid 955 (60) 171 (57) 1.14 (0.89–1.46)
Rifampicin 183 (12) 16 (5) 2.31 (1.37–3.92)b
Streptomycin 1,025 (65) 176 (59) 1.28 (1.00–1.65)
Ethambutol 66 (4) 6 (2) 2.36 (1.00–5.58)
Pyrazinamide 61 (4) 19 (6) 0.64 (0.36–1.12)
Multidrug resistance  (at least isoniazid and rifampicin) 156 (10) 11 (4) 2.86 (1.53–5.34)b
Other
Previously treated patients with acquired drug resistancec 106 (8) 16 (6) 1.38 (0.80–2.37)
Mean number of years between diagnosis and previous treatment (SD)d 7 (9) 22 (19) 0.93 (0.91–0.96)b
CI: confidence interval; SD: standard deviation.
a  Data are presented as number (percentage), unless indicated otherwise.
b  P<0.05.
c  Data were missing for some previously treated patients (242 foreign-born; 26 born in the Netherlands).
d  Calculated for patients with acquired drug resistance.
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an increase has also been observed in other countries 
[19]. Furthermore, next to certain ‘host-related factors’ 
[20], M. tuberculosis in general might have gained a 
higher ability to withstand treatment, resulting in more 
persistent infections and higher rates of transmission 
to other people. Possibly, particular resistance muta-
tions might be less deleterious than others or certain 
compensatory mutations might make up for any loss 
of fitness caused by the resistance mutation [21,22]. 
Borrell et al. demonstrated that the most common iso-
niazid resistance-conferring mutation in clinical set-
tings reduced isoniazid activation while maintaining 
virulence in mice [23].
The pronounced increase in resistance to regularly 
used drugs is considered highly relevant as these are 
the cornerstone of treatment and may perhaps reflect 
a trend in other European countries where large num-
bers of migrants are received [3,24]. Although MDR-TB 
is diagnosed relatively rarely in the Netherlands [6], 
we should closely monitor the seemingly increasing 
MDR-TB trend, as its treatment is costly, complicated 
and enduring [3]. In Europe, trends in MDR-TB over the 
past five years have differed substantially by coun-
try [3]. The MDR-TB rate remained stable in European 
Union/European Economic Area (EU/EEA) countries 
(4.5% in 2011), while in non-EU/EEA countries, it 
increased from 20.3% in 2007 to 30.2% in 2011.
The 23% drug resistance among previously treated 
patients found in our study was similar to the median 
prevalence of resistance in previously treated patients 
found in a recent global surveillance project (25.1%) 
[8]. Our finding that resistance in M. tuberculosis 
was mainly the result of transmission was also in line 
with global findings [25]. In 129 of 784 clustered PDR 
cases, cluster investigation confirmed transmission 
of resistance in the Netherlands, despite the meas-
ures to prevent TB transmission such as contact trac-
ing and screening of risk groups.  Among foreign-born 
cases, clustering does not always reflect transmis-
sion in the Netherlands. In particular, clustered cases 
originating from the same foreign country might have 
been infected in their home country by strains of the 
predominant genotypes in those countries. This could 
also be an explanation for the low percentage of for-
eign-born PDR cases with a confirmed epidemiological 
link. In general, the proportion of patients definitely 
infected in the Netherlands is presumably underesti-
mated, as transmission in a public space often remains 
unconfirmed in epidemiological cluster investigations. 
Furthermore, cluster investigation in foreign-born 
cases can be hindered by communication difficulties 
[26].
There are limitations associated with this study. Firstly, 
drug resistance trends could have been influenced by 
the change in DST method in 2004. However, the most 
Table 3
Comparison of rates of resistance to various antituberculosis drugs in patients with acquired and primary drug resistancea 
among 1,622 patients diagnosed with drug-resistant tuberculosis, the Netherlands, 1993–2011
Characteristic
Acquired DR
n=122
Primary DR 
n=1,500 Crude OR 
(95% CI)
Adjusted ORc 
(95% CI)
n (%)b n (%)b
Drug resistance
Isoniazid 86 (70) 882 (59) 1.67 (1.12–2.50)d 1.87 (0.83–4.18)
Rifampicin 36 (30) 130 (9) 4.41 (2.87–6.76)d 3.02 (1.43–6.38)d
Streptomycin 72 (59) 953 (64) 0.82 (0.57-1.20) 1.27 (0.67–2.43)
Ethambutol 17 (14) 47 (3) 3.86 (2.07–7.22)d 1.40 (0.57–3.47)
Pyrazinamide 8 (7) 53 (4) 1.49 (0.67–3.33) 1.32 (0.54–3.22)
Multidrug resistance (isoniazid and rifampicin) 32 (26) 109 (7) 4.53 (2.90–7.09)d 5.43 (3.39–8.65)d,e
Other
Mean age in years (SD) 39 (16) 33 (15) 1.02 (1.01–1.03)d 1.03 (1.01–1.05)d
Foreign born 106 (87) 1,242 (83) 1.38 (0.80–2.37) 1.68 (0.66–4.30)
Median duration of stay in the Netherlands in years (IQR)f 2 (0–11) 4 (1–10) 1.00 (0.98–1.02) 0.99 (0.96–1.03)
CI: confidence interval; DR: drug resistance; IQR: interquartile range; OR: odds ratio; SD: standard deviation; TB: tuberculosis.
a  Acquired drug resistance refers to resistance in previously treated TB cases; primary drug resistance refers to drug resistance in new TB 
cases.
b  Data are presented as number (percentage), unless indicated otherwise.
c  Adjusted for drug-specific resistance, age and being foreign-born.
d  P<0.05.
e  Adjusted for age and being foreign-born.
f  Calculated for foreign-born patients.
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pronounced increase in resistance was seen in the 
period since 2005, in which only the MGIT DST method 
was used. Moreover, DST at the National Reference 
Laboratory in the Netherlands has always been checked 
by WHO proficiency testing. Secondly, pyrazinamide 
susceptibility testing was less reliable before 2009 
and may therefore have had an effect on the results. 
However, due to the rare occurrence of pyrazinamide 
resistance, this probably had little effect on the overall 
trends. Thirdly, misclassification of ADR and PDR cases 
could have occurred because the classification was 
based on self-reported treatment history. Fourthly, 
14% of all patients with drug-resistant TB could not be 
classified as ADR or PDR at all, because their treatment 
history was unknown. Besides, ADR cases could have 
been PDR cases if they were reinfected with a resistant 
strain that differed from the strain they were previously 
treated for. For instance, a previous study has shown 
that reinfection with a different strain occurred in 16% 
of all patients with Dutch nationality who had been 
infected before 1981 [27]. Additionally, ADR patients 
born in the Netherlands whose parents had been born 
abroad could have acquired resistance in their parents’ 
country of origin, when visiting friends and family. The 
same may apply to patients who may have worked in 
a high TB burden country. On the other hand, the 14 
foreign-born ADR cases with unknown place of previ-
ous treatment could have acquired resistance in the 
Netherlands. Lastly, for 454 patients who were part of 
clusters whose data could not be matched to that of 
Figure 3
Classification model to determine the place of infection for tuberculosis patients with primary drug-resistant strains, the 
Netherlands, 1993–2011 
 
 
1. Is the patient a case in a cluster? 
2. Is the patient the first case in the cluster? 
Yes (n=784) No (n=661) 
Patient infected abroad or 
before 1993. n= 661 (45.7%) 
No (n=601) 
Patient infected abroad or 
before 1993. n= 183 (12.7%) 
1,445 primary drug-resistant cases 
Yes 
3. Is there a preceding pulmonary 
TB case in the same cluster? 
Patient infected abroad or 
before 1993. n= 68 (4.7%) 
No 
4. Is the patient a secondary case 
with a confirmed or likely 
epidemiological link with a 
preceding case in the cluster? 
Yes (n=533) 
Yes No 
Patient possibly infected in the 
Netherlands. n= 404 (28.0%) 
Patient definitely infected in 
the Netherlands. n=129 (8.9%) 
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the National Reference Laboratory, the place of trans-
mission could not be determined.
In conclusion, the increase in resistance of M. tuber-
culosis among patients born in the Netherlands and 
the recent increase among foreign-born patients have 
not led to an increase in the incidence of TB in the 
Netherlands, as the incidence has remained stable over 
the last few years [6]. With a high degree of transmis-
sion of resistant strains abroad and a large proportion 
of M. tuberculosis drug resistance among migrants, 
the problem of resistance in the Netherlands is closely 
related to the resistance problems in the migrants’ 
countries of origin. This highlights the importance of 
early detection of TB, resistance screening and treat-
ment programmes, especially in migrants originating 
from high-endemic countries with a high resistance 
rate. In these countries, preventive measures such as 
improved case detection, individualised treatment and 
improved drug supply and distribution could reduce the 
risk of acquiring resistance and its subsequent trans-
mission. Our findings may be representative of the sit-
uation in other low-endemic European countries with a 
relatively large proportion of migrants. Generally, only 
little is known about trends in resistance as testing 
and reporting is currently not sufficiently frequent or 
complete in many countries. The capacity to respond 
adequately to the threat of drug-resistant TB requires 
more detailed information on the magnitude of this 
problem. Therefore more research is needed in other 
European countries. Resistance monitoring and surveil-
lance remain highly important activities.
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